1. Home
  2. ITRM vs AEON Comparison

ITRM vs AEON Comparison

Compare ITRM & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iterum Therapeutics plc

ITRM

Iterum Therapeutics plc

HOLD

Current Price

$0.03

Market Cap

24.3M

Sector

Health Care

ML Signal

HOLD

Logo AEON Biopharma Inc.

AEON

AEON Biopharma Inc.

HOLD

Current Price

$0.93

Market Cap

25.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ITRM
AEON
Founded
2015
N/A
Country
Ireland
United States
Employees
N/A
8
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.3M
25.8M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ITRM
AEON
Price
$0.03
$0.93
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$9.00
$7.20
AVG Volume (30 Days)
30.9M
130.6K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
57.43
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$947.65
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.03
$0.43
52 Week High
$1.16
$1.45

Technical Indicators

Market Signals
Indicator
ITRM
AEON
Relative Strength Index (RSI) 26.10 41.62
Support Level N/A $0.91
Resistance Level $0.39 $1.12
Average True Range (ATR) 0.02 0.07
MACD -0.01 0.00
Stochastic Oscillator 3.34 34.33

Price Performance

Historical Comparison
ITRM
AEON

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

About AEON AEON Biopharma Inc.

AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.

Share on Social Networks: